---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056291"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:02:54.316608+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Corbus updates risk factors; no new operational or financial events

## Summary
- Filing supplements risk factors for Q1 2024; no change in business outlook.
- Highlights dependence on contract manufacturers and CROs for clinical supply.
- Notes exposure to U.S.-China trade policies and proposed BIOSECURE bill through CSPC license.
- Repeats standard IP infringement litigation risks; no suits filed.

## SEC filing metadata
- accession: 0000950170-24-056291
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024056291/0000950170-24-056291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024056291/crbp-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056291
- JSON: https://secwatch.observer/filing/0000950170-24-056291.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.